Esperion Therapeutics, Inc., a pharmaceutical company, develops and markets drugs for the treatment of patients with high low-density lipoprotein cholesterol in the United States and internationally. The company is headquartered in Ann Arbor, Michigan.
| Revenue (TTM) | $418.24M |
| Gross Profit (TTM) | $241.70M |
| EBITDA | $75.89M |
| Operating Margin | -8.22% |
| Return on Equity | -260.80% |
| Return on Assets | 12.00% |
| Revenue/Share (TTM) | $1.89 |
| Book Value | $-1.23 |
| Price-to-Book | 98.42 |
| Price-to-Sales (TTM) | 1.93 |
| EV/Revenue | 2.151 |
| EV/EBITDA | 11.32 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 23.20% |
| Shares Outstanding | $257.43M |
| Float | $255.18M |
| % Insiders | 0.68% |
| % Institutions | 69.78% |
Volatility is currently contracting